Back to top
more

Assembly Biosciences (ASMB)

(Delayed Data from NSDQ)

$12.65 USD

12.65
29,550

-0.71 (-5.31%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $12.39 -0.26 (-2.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 252)

Industry: Medical - Generic Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for ASMB

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Assembly Biosciences, Inc. [ASMB]

Reports for Purchase

Showing records 1 - 20 ( 23 total )

Company: Assembly Biosciences, Inc.

Industry: Medical - Generic Drugs

Record: 1

11/09/2023

Company Report

Pages: 7

3Q Recap; With Gilead Collaboration in Place, Assembly to Have Four Clinical Programs By Year-end 2024; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Assembly Biosciences, Inc.

Industry: Medical - Generic Drugs

Record: 2

10/18/2023

Daily Note

Pages: 4

Collaboration Agreement With Gilead Provides $100M Cash Infusion And Two New Candidates; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Assembly Biosciences, Inc.

Industry: Medical - Generic Drugs

Record: 3

10/03/2023

Daily Note

Pages: 4

Entry Inhibitor ABI-6250 Selected As HDV Candidate; Awaiting HSV Program to Enter The Clinic in 1H24; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Assembly Biosciences, Inc.

Industry: Medical - Generic Drugs

Record: 4

09/25/2023

Daily Note

Pages: 5

2023 International HBV Meeting Presentations Highlight Potential of Assembly''s HBV/HDV Programs; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Assembly Biosciences, Inc.

Industry: Medical - Generic Drugs

Record: 5

08/10/2023

Company Report

Pages: 7

2Q Recap; Herpesvirus Program ABI-5366 Enters The Clinic in 1H24; Second Candidate Nomination in 2H23; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Assembly Biosciences, Inc.

Industry: Medical - Generic Drugs

Record: 6

07/19/2023

Daily Note

Pages: 5

ABI-5366 Shows Potency Against HSV-1 and HSV-2 in First Preclinical Data; Entering the Clinic in 1H24; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Assembly Biosciences, Inc.

Industry: Medical - Generic Drugs

Record: 7

05/08/2023

Company Report

Pages: 7

1Q Recap; Herpesvirus Candidate ABI-5366 Expected to Enter the Clinic in 1H24; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Assembly Biosciences, Inc.

Industry: Medical - Generic Drugs

Record: 8

04/19/2023

Company Report

Pages: 7

Focus Turns to Programs With Shorter Time to Inflection Points; Core Inhibitor Program Shelved; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Assembly Biosciences, Inc.

Industry: Medical - Generic Drugs

Record: 9

03/24/2023

Company Report

Pages: 8

4Q Recap; 4334 Takes Over As Lead Core Inhibitor Program; 3733 On Pause Due to Non-Clinical Toxicity; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Assembly Biosciences, Inc.

Industry: Medical - Generic Drugs

Record: 10

12/29/2022

Daily Note

Pages: 3

Interim Data on HBV Core Inhibitors Are Early but Highly Encouraging; Next Datasets Expected in 1Q23; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Assembly Biosciences, Inc.

Industry: Medical - Generic Drugs

Record: 11

11/09/2022

Company Report

Pages: 8

3Q Recap; 4334 Enters The Clinic Following CTA Approval; 3733 Phase 1b Initial Data by Year-End; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Assembly Biosciences, Inc.

Industry: Medical - Generic Drugs

Record: 12

09/01/2022

Daily Note

Pages: 4

Assembly Unveils Two New Herpesvirus Programs; Clinical Candidate Identification Expected in 2023; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Assembly Biosciences, Inc.

Industry: Medical - Generic Drugs

Record: 13

08/10/2022

Company Report

Pages: 8

2Q Recap; Core Inhibitor Studies Ongoing; Diversifies Portfolio With New Non-HBV Viral Program in 3Q22; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Assembly Biosciences, Inc.

Industry: Medical - Generic Drugs

Record: 14

07/27/2022

Daily Note

Pages: 5

New Oral Interferon Agonist Program for HBV Unveiled; Third New Program Expected in 3Q22; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Assembly Biosciences, Inc.

Industry: Medical - Generic Drugs

Record: 15

07/21/2022

Company Report

Pages: 6

With Vebicorvir Gone and Workforce Right-Sized, Assembly Now All-In on ''3733 and ''4334; PT to $2.50

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Assembly Biosciences, Inc.

Industry: Medical - Generic Drugs

Record: 16

06/23/2022

Daily Note

Pages: 4

EASL Presentations Highlight Clinical Potential of Assembly''s Core Inhibitor Programs; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Assembly Biosciences, Inc.

Industry: Medical - Generic Drugs

Record: 17

05/13/2022

Company Report

Pages: 9

1Q Recap; Following New HDV Program, New HBV Non- Core Inhibitor Target to Be Unveiled in June; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Assembly Biosciences, Inc.

Industry: Medical - Generic Drugs

Record: 18

03/14/2022

Company Report

Pages: 9

4Q Recap; Assembly to Unveil Next Approach to HBV in KOL Event on March 31

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Assembly Biosciences, Inc.

Industry: Medical - Generic Drugs

Record: 19

01/05/2022

Daily Note

Pages: 5

2022 Pipeline Milestones; Plans to Diversify From the Core Inhibition MoA, and Indeed Beyond HBV

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Assembly Biosciences, Inc.

Industry: Medical - Generic Drugs

Record: 20

11/05/2021

Company Report

Pages: 9

3Q21 Recap; Interim Data From All Three VBR Triple Combination Studies Expected in 2022; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party